The European Commission has offered EU member states to purchase 200 million additional doses of the Covid-19 vaccine produced by BioNTech and Pfizer, with the possibility of acquiring an additional 100 million doses. This would allow the EU to purchase up to 600 million doses of this vaccine, which is already in use across the Union.
This is stated in a note from the European Commission. The additional doses will be delivered starting in the second quarter of 2021.
The president of the EU Commission Ursula von der Leyen announced at a press conference: "We now have agreed with BioNTech and Pfizer to extend this contract. With the new agreement we could purchase a total of up to an additional 300 million doses of the BioNTech vaccine."
Of the 300 million other doses ordered by the EU under a new contract with BioNTech-Pfizer, "75 million doses will be delivered in the second quarter of 2021. Our goal is to get the maximum number of Europeans vaccinated as quickly as possible". Regarding vaccines, "there will be no parallel negotiations or parallel contracts, we are negotiating together and together we will carry out the vaccination process . We have a binding agreement".
The EU has acquired an extensive portfolio of vaccines based on different technologies. It has obtained up to 2.3 billion doses of the most promising vaccines under development for Europe and neighboring countries.
In addition to the BioNTech-Pfizer vaccine, a second vaccine, manufactured by Moderna, was authorized on January 6, 2021. Other vaccines are expected to be approved soon. This vaccine portfolio will allow the EU to cover the needs of the entire population and supply vaccines to neighboring countries.